• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Anthem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    10/19/22 6:04:34 AM ET
    $ANTM
    Medical Specialities
    Health Care
    Get the next $ANTM alert in real time by email
    8-K
    false 0001156039 0001156039 2022-10-19 2022-10-19

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): October 19, 2022

     

     

    Elevance Health, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Indiana   001-16751   35-2145715

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    220 Virginia Ave

    Indianapolis, IN 46204

    (Address of principal executive offices) (Zip Code)

    Registrant’s telephone number, including area code: (833) 401-1577

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock   ELV   NYSE

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 2.02

    Results of Operations and Financial Condition.

    On October 19, 2022, Elevance Health, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

    None of the information furnished in Item 2.02 or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    No.

      

    Exhibit

    99.1    Press Release, dated October 19, 2022, reporting Elevance Health, Inc. financial results for the quarter ended September 30, 2022.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    FORWARD-LOOKING STATEMENTS

    This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent otherwise required by federal securities laws, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof. These risks and uncertainties include, but are not limited to: the impact of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19, and catastrophes; trends in healthcare costs and utilization rates; our ability to secure sufficient premium rates, including regulatory approval for and implementation of such rates; the impact of federal, state and international law and regulation, including changes in the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; our ability to contract with providers on cost-effective and competitive terms; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; reduced enrollment; the impact of a cyber-attack or other cyber security breach resulting in unauthorized disclosure of member or employee sensitive or confidential information, including the impact and outcome of any investigations, inquiries, claims and litigation related thereto; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; risks and uncertainties related to our pharmacy benefit management (“PBM”) business, including non-compliance by any

     

    2


    party with the PBM services agreement between us and CaremarkPCS Health, L.L.C.; medical malpractice or professional liability claims or other risks related to healthcare and PBM services provided by our subsidiaries; general risks associated with mergers, acquisitions, joint ventures and strategic alliances; changes in tax laws; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; failure to effectively maintain and modernize our information systems; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

     

     

    3


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Dated: October 19, 2022

     

    ELEVANCE HEALTH, INC.

    By:

     

    /s/ Kathleen S. Kiefer

    Name:   Kathleen S. Kiefer
    Title:   Corporate Secretary
    Get the next $ANTM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANTM

    DatePrice TargetRatingAnalyst
    6/22/2022$607.00 → $533.00Overweight → Equal-Weight
    Morgan Stanley
    6/17/2022$550.00Buy
    Loop Capital
    5/27/2022$577.00 → $596.00Outperform
    Bernstein
    2/7/2022$475.00 → $500.00Buy
    Argus Research
    1/28/2022$561.00 → $518.00Overweight
    Morgan Stanley
    1/27/2022$430.00 → $465.00Market Perform
    SVB Leerink
    12/20/2021$450.00 → $510.00Neutral → Buy
    Mizuho
    12/17/2021$486.00 → $561.00Overweight
    Morgan Stanley
    More analyst ratings

    $ANTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Anthem Inc. (Amendment)

      SC 13G/A - Anthem, Inc. (0001156039) (Subject)

      2/9/22 3:24:47 PM ET
      $ANTM
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Anthem, Inc. (0001156039) (Subject)

      2/10/21 10:30:29 AM ET
      $ANTM
      Medical Specialities
      Health Care

    $ANTM
    Leadership Updates

    Live Leadership Updates

    See more
    • Treace Medical Concepts Appoints New Directors

      PONTE VEDRA, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced the appointment of Betsy Hanna and Deepti Jain to its Board of Directors effective October 1, 2021. "With decades of combined experience in healthcare leadership, Ms. Hanna and Ms. Jain strengthen the expertise of our Company's Board of Directors," said James T. Treace, the Company's Chairman of the Board. "Our executive leadership and board are pleased to add two individuals with their stellar reputa

      10/4/21 8:00:00 AM ET
      $ANTM
      $TCMD
      $TMCI
      Medical Specialities
      Health Care
      Medical/Dental Instruments
    • David P. Abney, Gail K. Boudreaux Named to Target Corporation's Board of Directors

      MINNEAPOLIS, Aug. 11, 2021 /PRNewswire/ -- Target Corporation (NYSE:TGT) announced today its board of directors elected David P. Abney, former chairman of the board and chief executive officer of United Parcel Service, Inc., and Gail K. Boudreaux, president and chief executive officer of Anthem, Inc., as directors. Mr. Abney's appointment is effective immediately and Ms. Boudreaux's appointment becomes effective September 23, 2021. Mr. Abney, 65, held a series of escalating leadership roles at UPS over his more than 40-year career. He was named CEO in September 2014 and chairman and CEO in February 2016, a role he held until announcing his retirement in June 2020. He remained executive chair

      8/11/21 4:05:00 PM ET
      $ANTM
      $TGT
      Medical Specialities
      Health Care
      Department/Specialty Retail Stores
      Consumer Discretionary
    • Dante Labs Announces Appointment of Healthcare Veteran and GRAIL SVP Mark Morgan to Board Of Directors to Support Genomic and Precision Medicine Scaling in the United States

      CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, announced today the appointment of Mark Morgan as a board member. Mark is the SVP of Market Access for GRAIL, which has developed a highly innovative multi-cancer, early detection blood test. "We are excited to welcome Mark Morgan to the Dante Labs Board," said Dante Labs CEO Andrea Riposati, "Mark is a rockstar in healthcare. His deep experience with health plans, coupled with market access expertise in both biopharma and diagnostics will be invaluable to Dante Labs as we continue to build on our global success and expansion in the United States." Mr. Morgan state

      8/9/21 7:39:23 AM ET
      $AMGN
      $ANTM
      $ILMN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities

    $ANTM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anthem Announces Subsidiary Brands Under Elevance Health

      Changes reflect the company's continued evolution to support whole health As Anthem, Inc. (ANTM) moves closer to rebranding to Elevance Health, Inc. later this month, the company today announced the launch of healthcare services brand Carelon and health plan brand Wellpoint to join the company's family of brands that includes Anthem Blue Cross and Blue Shield. The move will optimize and streamline the company's brand portfolio, reduce complexities, and further underscore its evolution to deliver solutions beyond traditional health insurance, simplify the healthcare experience, and advance health beyond healthcare. "An important part of being a lifetime, trusted health partner is grounded

      6/15/22 10:00:00 AM ET
      $ANTM
      Medical Specialities
      Health Care
    • Anthem, Inc. Aims to Enhance Maternal Health with New Digital-First Solution

      Anthem partners with Happify Health to bring innovative digital health services to areas of women's health including pregnancy, menopause, and more Anthem, Inc. (NYSE:ANTM), a leading health company dedicated to improving lives and communities, will add to its ongoing support of the whole health of women with the addition of a new a digital-first solution in select markets. This program, a collaboration between Anthem – soon to be Elevance Health on June 28 – and Happify Health, bridges the gap between the unique physical and mental health concerns women face. It is part of Anthem's early and consistent support of women throughout the entirety of their maternal health journey with solution

      6/7/22 7:55:00 AM ET
      $ANTM
      Medical Specialities
      Health Care
    • Anthem Announces Appearance at Upcoming Conference

      Anthem, Inc. (NYSE:ANTM) announced today that senior management is scheduled to present at the 38th Annual Bernstein Strategic Decisions Conference in New York City on June 3, at 8:00 a.m. Eastern Daylight Time (EDT). All interested parties are invited to listen to a webcast of the presentation by visiting www.antheminc.com and selecting the "Investors" link. Following the presentation, a webcast replay will be available for two weeks. To listen to the live webcast, please visit Anthem's website at least 15 minutes early to download and install any necessary audio software. Individuals who listen to the presentations will be presumed to have read Anthem's most recent filings with the SEC,

      5/26/22 4:05:00 PM ET
      $ANTM
      Medical Specialities
      Health Care

    $ANTM
    SEC Filings

    See more
    • Anthem Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Elevance Health, Inc. (0001156039) (Filer)

      11/4/22 4:16:09 PM ET
      $ANTM
      Medical Specialities
      Health Care
    • SEC Form 424B3 filed by Anthem Inc.

      424B3 - Elevance Health, Inc. (0001156039) (Filer)

      10/27/22 4:22:42 PM ET
      $ANTM
      Medical Specialities
      Health Care
    • SEC Form FWP filed by Anthem Inc.

      FWP - Elevance Health, Inc. (0001156039) (Subject)

      10/26/22 5:22:59 PM ET
      $ANTM
      Medical Specialities
      Health Care

    $ANTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Anthem downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Anthem from Overweight to Equal-Weight and set a new price target of $533.00 from $607.00 previously

      6/22/22 7:17:32 AM ET
      $ANTM
      Medical Specialities
      Health Care
    • Loop Capital initiated coverage on Anthem with a new price target

      Loop Capital initiated coverage of Anthem with a rating of Buy and set a new price target of $550.00

      6/17/22 7:14:30 AM ET
      $ANTM
      Medical Specialities
      Health Care
    • Bernstein resumed coverage on Anthem with a new price target

      Bernstein resumed coverage of Anthem with a rating of Outperform and set a new price target of $596.00 from $577.00 previously

      5/27/22 7:11:36 AM ET
      $ANTM
      Medical Specialities
      Health Care

    $ANTM
    Financials

    Live finance-specific insights

    See more

    $ANTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Anthem, Inc. Completes Acquisition of Integra Managed Care

      Anthem, Inc. (NYSE:ANTM) today announced the completion of its acquisition of Integra Managed Care, a Managed Long-Term Care Plan in New York that helps adults with long term care needs and disabilities live safely and independently in their own home. "We're pleased to complete this acquisition and work alongside our new colleagues as we continue to grow our Medicaid business and enhance the healthcare experience for all of our members," said Felicia Norwood, Executive Vice President of Anthem's Government Business Division. "Anthem and Integra's shared commitment to deliver high quality, comprehensive whole-health care across communities throughout New York ensures that our members will c

      5/5/22 7:48:00 AM ET
      $ANTM
      Medical Specialities
      Health Care
    • Anthem Reports First Quarter 2022 Results, Reflecting Strong Momentum Across All Divisions

      First quarter GAAP net income was $7.39 per share, including net negative adjustment items of $0.86 per share. Adjusted net income was $8.25* per share. Operating revenue grew by 18.0% over the prior year quarter to $37.9 billion. Operating gain grew by 13.2% over the prior year quarter to $2.4 billion. Medical enrollment increased by 3.3 million members year-over-year and 1.4 million members sequentially to 46.8 million members. Second quarter 2022 dividend of $1.28 per share declared to shareholders. Anthem, Inc. (NYSE:ANTM) reported first quarter 2022 results reflecting strong financial performance, including double-digit top and bottom line growth. "Our strong momentum a

      4/20/22 6:00:00 AM ET
      $ANTM
      Medical Specialities
      Health Care
    • Anthem to Hold Conference Call and Webcast to Discuss First Quarter Results on April 20, 2022

      Anthem, Inc. (NYSE:ANTM) will release first quarter 2022 financial results on April 20, 2022, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 (Domestic) 800-813-5525 (Domestic Replay) 312-470-0178 (International) 203-369-3346 (International Replay) The access code for the call is 3972058. There is no access code for the replay. The replay will be available from 11:30 a.m. EDT on April 20, 2022 until the end of the day on May 20, 2022. The cal

      4/6/22 4:05:00 PM ET
      $ANTM
      Medical Specialities
      Health Care
    • SEC Form 4: Todt Blair Williams was granted 3,983 shares, increasing direct ownership by 93% to 8,283 units

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      1/5/23 5:03:57 PM ET
      $ANTM
      Medical Specialities
      Health Care
    • SEC Form 4: Norwood Felicia F covered exercise/tax liability with 1,754 shares, decreasing direct ownership by 6% to 26,684 units

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      1/4/23 4:50:33 PM ET
      $ANTM
      Medical Specialities
      Health Care
    • SEC Form 4: Todt Blair Williams covered exercise/tax liability with 117 shares, decreasing direct ownership by 3% to 4,300 units

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      12/5/22 4:53:39 PM ET
      $ANTM
      Medical Specialities
      Health Care